Atisama Therapeutics reported that its experimental drug RB042 has progressed to multiple ascending dose cohorts in a phase 1 clinical ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE